BIO Statement on HHS Dismissal of CDC Advisory Committee Members

June 9, 2025

WASHINGTON, D.C. - John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding today’s dismissal of the voting members of the CDC Advisory Committee on Immunization Practices:  

 

“The Advisory Committee on Immunization Practices (ACIP) is vital to ensuring scientific rigor and third-party experts inform decisions about the safe and effective use of vaccines in the US. Under the law, ACIP also plays a critical role determining how the American people access immunizations. 


We are greatly concerned about the uncertainty created by the abrupt dismissal of the serving committee members and the loss of years of experience, especially less than three weeks before the next ACIP meeting, with consequential votes on recommendations that will affect Americans’ access to RSV, flu, HPV and other important vaccines. 


While the advisors serve on the ACIP at the selection and appointment by the Secretary, the removal of committee members will cause significant disruption in this critical process. Immunization reviews take place through working groups over many months, culminating with discussion during a public meeting. A wholesale change of this manner will negatively affect the Committee’s ability to deliberate and make well-informed recommendations, putting American lives at risk.   


We agree that transparency is key to restoring trust in immunizations; however, the actions taken today upend a time-tested system that has protected American public health.” 


### 


September 11, 2025
Members are invited to join G2G’s Monthly GBG Reporting Service Webinar on September 18, 2025 . The first portion ( 12:00–12:30 PM ET ) is free and open to all, offering a high-level overview of current federal funding trends. The second half ( 12:30–1:00 PM ET ) is a premium consultation available only to Georgia Life Sciences members, offering direct access to G2G’s expert team—who have helped secure over $550 million in non-dilutive government funding since 2007. Register here: https://www.g2gconsulting.com/event/non-dilutive-funding-g2gs-monthly-gbg-reporting-service-webinar-14-3/2025-09-18/ Key opportunities this month include DARPA’s Expedited Research Innovation System for CBRN threat defense technologies, BARDA’s I-CREATE diagnostic funding and VANGUARD biomanufacturing tools development (each offering up to $200,000), NIAID tuberculosis and influenza research units (up to $1.5–$2.5 million annually), DoD’s $4 million Advanced Medical Monitor development through MTEC, and multiple SBIR opportunities for sensors and field-deployable diagnostics (up to $209,575 for Phase I awards). The September GBG report highlights 13 immunology and infectious disease opportunities, 10 cognitive and brain health programs, and several biotechnology and biomanufacturing initiatives across federal agencies including the Army, ARPA-H, BARDA, and NSF. Georgia Life Sciences members can access the complete 29-page report with detailed deadlines and eligibility requirements [insert link or portal instructions here]. GLS members can access the full 29-page report with deadlines and submission details by logging into your member portal.
By Maria Thacker Goethe September 5, 2025
Protecting U.S. Leadership in Agricultural Biotechnology
By Maria Thacker Goethe August 29, 2025
Celebrating the Next Generation of Scientific Breakthroughs in Georgia
MORE POSTS